![](/img/cover-not-exists.png)
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, OanaVolume:
13
Language:
english
Journal:
Cost Effectiveness and Resource Allocation
DOI:
10.1186/s12962-015-0037-9
Date:
December, 2015
File:
PDF, 1.61 MB
english, 2015